Mavacamten
Mavacamten structure
|
Common Name | Mavacamten | ||
|---|---|---|---|---|
| CAS Number | 1642288-47-8 | Molecular Weight | 273.330 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C15H19N3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MavacamtenMavacamten is a modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively. |
This table lists Chinese names, IUPAC names and various aliases of this chemical substance.
| Name | mavacamten |
|---|---|
| Synonym | More Synonyms |
This table contains bioactivity, target information and biological‑assay experimental data of this compound.
| Description | Mavacamten is a modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 490 nM (bovine cardiac), 711 nM (human cardiac)[1]. |
| In Vitro | Mavacamten is found to have an IC50 value of 490 nM in the bovine system, 711 nM in the human system, and 2140 nM in the rabbit system, indicating selectivity of >4-fold for cardiac myosin[1]. |
| In Vivo | Treatment with Mavacamten reduces FS from 52±3% to 38±7%. Treatment with Mavacamten reduces FS from 81±7% to 60±13%, corresponding to a relative reduction of 25%. Across all measurements there is a linear correlation between FS and Mavacamten plasma concentrations with each 100 ng/mL increase in Mavacamten concentration lowering FS by 4.9%. Treatment with Mavacamten eliminates SAM in 5/5 subjects, whereas SAM persists in 3/3 subjects treated with vehicle alone. Pressure gradients across the LVOT drop to 11.1±5.0 mmHg with Mavacamten treatment; whereas vehicle treated cats maintain stable LVOT pressure gradients[2]. Mavacamten reduces contractility by decreasing the adenosine triphosphatase activity of the cardiac myosin heavy chain. Chronic administration of Mavacamten suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain[3]. |
| Animal Admin | Cats[2] Five cats are selected for study. At the completion of imaging, a tenminute intravenous infusion of Mavacamten (MYK-461 (n=5)) at 0.3 mg/kg/hr IV is started. Focused echocardiography is performed after five minutes. After ten minutes, the Mavacamten infusion rate is lowered to 0.12 mg/kg/hr IV, a blood sample is drawn and an echocardiogram performed. If ventricular function remains hypercontractile or within normal limits by visual inspection, another blood sample is obtained and the Mavacamten infusion rate is increased to 0.36 mg/kg/hr IV for ten minutes. Focused echocardiography is performed after five minutes. After ten minutes, the Mavacamten infusion rate is lowered to 0.15 mg/kg/hr IV, a blood sample is drawn and an echocardiogram performed. Following imaging, the isoproterenol infusion is discontinued. When heart rate returns to baseline levels, a complete echocardiogram is performed on Mavacamten alone. Study drug is then discontinued, and animals are awakened, extubated and moved to recovery. Three of five cats are available to return for a control arm of this experiment after a 6-week washout period[2]. |
| References |
This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Molecular Formula | C15H19N3O2 |
| Molecular Weight | 273.330 |
| Exact Mass | 273.147736 |
| LogP | 2.65 |
| Index of Refraction | 1.591 |
| InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |
| SMILES | CC(Nc1cc(=O)n(C(C)C)c(=O)[nH]1)c1ccccc1 |
| Storage condition | 2-8℃ |
This table contains target information, in‑vitro & in‑vivo assay data for this compound.
This table collects all English aliases, systematic names and CAS‑related synonyms of the compound.
| 3-Isopropyl-6-{[(1S)-1-phenylethyl]amino}-2,4(1H,3H)-pyrimidinedione |
| QX45B99R3J |
| mavacamten |
This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.
| Q: What is the InChIKey of mavacamten? |
| A: InChIKey of mavacamten is RLCLASQCAPXVLM-NSHDSACASA-N. |
| Q: What are the uses of mavacamten? |
| A: Main uses of mavacamten: Mavacamten is a modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively. |
| Q: What is the English name of mavacamten? |
| A: The English name of mavacamten is mavacamten. |
| Q: What is the LogP of mavacamten? |
| A: LogP of mavacamten is 2.65. |
| Q: What are the storage conditions for mavacamten? |
| A: Storage conditions for mavacamten: 2-8℃. |
| Q: What is the SMILES notation of mavacamten? |
| A: SMILES notation of mavacamten is CC(Nc1cc(=O)n(C(C)C)c(=O)[nH]1)c1ccccc1. |
| Q: What is the CAS number of mavacamten? |
| A: CAS number of mavacamten is 1642288-47-8. |
| Q: What is the molecular weight of mavacamten? |
| A: Molecular weight of mavacamten is 273.330. |
| Q: What is the molecular formula of mavacamten? |
| A: Molecular formula of mavacamten is C15H19N3O2. |
| Q: What English synonyms does mavacamten have? |
| A: English synonyms of mavacamten: 3-Isopropyl-6-{[(1S)-1-phenylethyl]amino}-2,4(1H,3H)-pyrimidinedione, QX45B99R3J, mavacamten. |
This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.
| Shanghai Nianxing Industrial Co., Ltd |